Evidence map›Paper›PMID 40407499›Full record

ArticlePharmacy (Basel, Switzerland)2025

Exploring Complementary Medicine Usage, Consumer Perceptions, and Impact of Label Warnings: A Cross-Sectional Study in Melbourne, Australia.

Kaveh Naseri, Thilini Thrimawithana, Ayman Allahham, Vivek Nooney, Barbora de Courten, Wejdan Shahin

Abstract read
In one paragraph

Article in Pharmacy (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kaveh NaseriDiscipline of Pharmacy, School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC 3083, Australia.ORCID 0000-0002-0511-8142
Thilini ThrimawithanaDiscipline of Pharmacy, School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC 3083, Australia.ORCID 0000-0003-3100-7187
Ayman AllahhamDiscipline of Pharmacy, School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC 3083, Australia.ORCID 0000-0001-7999-8077
Vivek NooneyDiscipline of Pharmacy, School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC 3083, Australia.
Barbora de CourtenDiscipline of Pharmacy, School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC 3083, Australia.ORCID 0000-0001-8760-2511
Wejdan ShahinDiscipline of Pharmacy, School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC 3083, Australia.ORCID 0000-0002-1859-7699

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Complementary medicines (CMs) are widely used worldwide, with usage rates ranging from 24% to 71.3%. Despite their popularity, many CMs lack robust scientific support and can potentially lead to adverse health effects. Limited research exists on CMs-related adverse events and the role of CMs' labels in conveying crucial information to consumers. This cross-sectional study investigated the usage, consumer perspectives, and influence of labels specifically on product-based CMs, including nutritional supplements, vitamins, minerals, probiotics, prebiotics, and herbal medicines. Practitioner-led therapies and mind-body practices were outside the scope of this research. Data were collected through an online questionnaire and analyzed using descriptive statistics and correlation analysis. The study enrolled 125 participants who were current CMs users. Pharmacies and supermarkets were the primary sources for CMs procurement. Participants' perceptions of CMs effectiveness and safety were positively correlated. Label warnings prompted participants to seek additional information, but consultation with healthcare professionals was infrequent. Adverse reactions were reported by 18.5% of participants, with self-management approaches being common. Label warnings play a significant role in prompting consumers to seek more information about CMs. However, the limited engagement of healthcare professionals, especially pharmacists, suggests an opportunity for improved consumer education and pharmacist involvement in CMs-related discussions. Addressing these aspects can lead to safer CMs practices and informed decision-making among consumers.

Indexed as

adverse reactionscomplementary medicinesconsumer perceptionslabel warning

Identifiers

PMID40407499
PMCPMC12101403

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.